Tosufloxacin

Drug Profile

Tosufloxacin

Alternative Names: A 60969; A 61827; Ozex; T-3262; Tosuxacin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Toyama Chemical
  • Class Antibacterials; Eye disorder therapies; Fluoroquinolones; Naphthyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Gram-negative infections; Gram-positive infections; Respiratory tract infections; Urinary tract infections

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 24 Feb 2010 Discontinued - Phase-II for Bacterial infections in USA (PO)
  • 31 Jan 2010 Registered for Bacterial infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top